China reports record wave of mosquito-borne chikungunya virus
BEIJING – A city in China's southern industrial hub has recorded 3,195 chikungunya cases so far in July, the country's biggest outbreak of the mosquito-borne virus since it first emerged in the mainland nearly two decades ago.
Foshan city – in Guangdong Province, just north of Hong Kong – first reported an imported chikungunya case earlier in July, China's national broadcaster CCTV said, citing briefings from the local authorities.
Infections have soared by more than 2,700 in the past week alone.
While Chinese health officials have yet to explain what's behind the outbreak, Guangdong has launched stricter anti-mosquito measures, including urging residents to clear stagnant water and make sure drainage channels remain unobstructed.
Chikungunya, first identified in 1952 in Tanzania, is transmitted to humans by infected mosquitoes, the World Health Organisation says.
The virus causes fever and severe joint pain, and other symptoms can include headaches, muscle pain, vomiting and fatigue.
The outbreak in Guangdong, an often hot and humid area of southern China, is the latest sign that tropical diseases – from dengue to malaria and zika – are expanding their reach, as climate change lets mosquitoes live in new territories that have become warmer and wetter.
Increased international travel and low population immunity are also helping the spread.
An explosion in cases in the Indian Ocean since the start of 2025 has sparked concerns of a spread to other countries, leading the WHO to issue an urgent call to action this week, Reuters reported.
France and Italy, thousands of miles from the region, have both found locally-acquired chikungunya cases this year.
'The surge in chikungunya cases is likely due to favourable climatic conditions that allow blooms of the Aedes mosquito population,' said Dr Robert Jones, Assistant Professor in the Department of Disease Control at the London School of Hygiene & Tropical Medicine.
'These are aggressive, day-biting mosquitoes that thrive in warm, wet conditions.'
More than five billion people live in areas across 119 countries at risk from chikungunya, the WHO told reporters in Geneva, Reuters said.
Some 220,000 cases and 80 related deaths have been reported in 14 countries and territories globally so far in 2025, according to the European Centre for Disease Prevention and Control.
China recorded its first chikungunya case in 2008, an imported infection detected at an airport in Guangdong.
The first locally transmitted cases – infecting 253 people – were reported in the province two years later.
Since then, only sporadic cases have been found, in Yunnan and Fujian provinces.
Globally, population susceptibility is likely elevated in areas where chikungunya outbreaks haven't tended to occur, said Ms Patricia Gallego Delgado, Associate Director at London-based disease forecasting firm Airfinity.
The wave is 'attributable to lower levels of population immunity, as individuals in these regions may have had limited or no prior exposure to the virus,' she said. BLOOMBERG
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
15 hours ago
- Straits Times
Malaysia considering nationwide vape ban, says Health Minister
Find out what's new on ST website and app. Terengganu and Perlis will ban the sale of vape products on Aug 1. KUALA LUMPUR - Putrajaya is considering a nationwide ban on the use and sale of e-cigarettes or vapes, according to Health Minister Dzulkefly Ahmad. Datuk Seri Dzulkefly stated that a special committee from the Health Ministry will propose the ban to address the abuse of electronic cigarettes. 'It will come in the form of a proposal where the ministry will bring this agenda to ban vapes,' said Dr Dzulkefly during a press conference in Parliament on July 28. He also mentioned the Control of Smoking Products for Public Health Act 2024 (Act 852), which regulates vape use. 'It does not cover the banning of vapes. I hope this can be clarified,' added Dr Dzulkefly. He also said the ban on vaping products requires careful assessment from legal, industry, government revenue, and licensing perspectives. 'We will also hold discussions with four main ministries: the Finance Ministry, Domestic Trade and Cost of Living Ministry, Investment, Trade and Industry Ministry, and the Attorney General's Chambers (AGC),' said Dr Dzulkefly, adding that a committee meeting was held recently on July 22. Dr Dzulkefly said his ministry welcomes the decision by six state governments - Johor, Kelantan, Terengganu, Perlis, Kedah, and Pahang - to stop issuing or renewing vape sales licence. Top stories Swipe. Select. Stay informed. Singapore Tanjong Katong sinkhole backfilled; road to be repaved after LTA tests Singapore MRT platform screen doors at 15 underground stations to undergo renewal Singapore 'Medium risk' of severe haze as higher agricultural prices drive deforestation: S'pore researchers Singapore Jail for former pre-school teacher who tripped toddler repeatedly, causing child to bleed from nose Singapore Police statements by doctor in fake vaccine case involving Iris Koh allowed in court: Judge Singapore Authorities say access to Changi intertidal areas unaffected by reclamation, in response to petition Singapore No change to SIA flights between S'pore and Cambodia, S'pore and Thailand, amid border dispute Singapore Not feasible for S'pore to avoid net‑zero; all options to cut energy emissions on table: Tan See Leng 'This is in line with public health aspirations and the premise licensing powers under local governments. This ruling is still limited and does not cover all premises, including grocery stores,' added Dr Dzulkefly. Meanwhile, Dr Dzulkefly said the Health Ministry is enforcing Act 852 which covers the registration of smoking and vaping products, a ban on underage individuals, and restrictions on the sale of smoking and vape products, among other measures. Up until June 30, the Health Ministry conducted 15,775 operations, issued 78,424 notices, and opened 524 investigation papers, according to Dr Dzulkefly. He added that there were 3,200 brands consisting of 6,800 variants of vaping products before the enforcement of Act 852, which began on Oct 1, 2024. 'Now, there are only 390 brands, consisting of 2,794 variants that were registered,' added Dr Dzulkefly. He also said that 2,619 smoking notices have been issued to underage smokers and 27 notices to underage individuals who bought smoking products. At the same time, Dr Dzulkefly said the Health Ministry has assisted 36,780 secondary school students in a smoking cessation intervention programme. '230 primary school students and 44,211 secondary school students have been identified for that programme. 'The 111 one-stop centres for addiction (OSCA) and 857 smoking cessation clinics are ready to serve,' he said. Dr Dzulkefly also said that beginning Aug 1, the Health Ministry will launch 'Selamat PaPa' (save the lungs) and 'Ops Selamatkan MaMa' (for passive smoking) to drive the agenda of smoking cessation. According to Dr Dzulkefly, this initiative is in response to the latest figures from the cancer registry from 2022 to 2023, which show 8,091 males and 5,251 females with lung cancer. 'The difference is not huge, and this reminds us that saving 'papa' is also about saving 'mama',' he added. Presently, Johor and Kelantan have completely banned the sale of vape products, while Kedah will stop issuing new licences for vape shops. Terengganu and Perlis will ban the sale of vape products on Aug 1. THE STAR/ASIA NEWS NETWORK
Straits Times
a day ago
- Straits Times
Forum: MOH supports healthcare providers in safeguarding patient databases
Find out what's new on ST website and app. We refer to Dr Yik Keng Yeong's letter ' Doctors may need help preventing cyber attacks on patient databases ' (July 22). Cyber security is a shared responsibility. Government systems such as the National Electronic Health Record (NEHR) are designed with robust cyber and data security measures in place to protect Singaporeans' health information. These include technical safeguards such as firewalls, security tools to detect and mitigate attacks, and ongoing monitoring and investigation of suspicious activities. In turn, systems connected to the NEHR are also required to have appropriate security measures in place. We understand the concern that GPs may have, and have ensured that white-listed clinic management systems meet the requisite cyber-security standards. Healthcare providers play an important role in ensuring that they have robust arrangements in place as to how their clinic management systems or electronic medical record systems are managed and used. They should put in place good practices, such as using strong passwords and two-factor authentication, be vigilant against phishing attempts, use anti-malware and anti-virus solutions, and keep computers/systems updated with security patches. The Ministry of Health supports healthcare providers through funding, and training and educational materials on cyber and data security practices. There are also the Cyber and Data Security Guidelines and Guidebook which help healthcare providers understand and meet the essential security requirements. The Ministry of Health is also exploring ways to work with cyber and data security providers to support healthcare providers in strengthening their security posture. We strongly encourage all healthcare providers to familiarise themselves with essential cyber and data security practices. Raymond Chua (Adjunct Professor) Deputy Director-General of Health (Health Regulation) Ministry of Health
Straits Times
a day ago
- Straits Times
What to know about 2 new Alzheimer's disease drugs approved in Singapore
Find out what's new on ST website and app. One factor that could stand in the way of wider acceptance of these drugs is their costliness. SINGAPORE – Tackling Alzheimer's disease in Singapore received a boost earlier in 2025, when the authorities approved two new drugs for the neurodegenerative disease. Although these drugs – lecanemab and donanemab – cannot cure or reverse the effects of Alzheimer's, they have been shown to slow the progression of the disease, which accounts for almost 70 per cent of dementia cases worldwide. Simply Science looks at what these drugs do, how effective they are, as well as the risks and costs. How do they work? The two new drugs are monoclonal antibodies, which are lab-produced proteins that mimic natural antibodies. They work by targeting and removing beta-amyloids – molecules that accumulate in the frontal cortex and hippocampus of the brain – causing Alzheimer's disease. Lecanemab, which is marketed as Leqembi, is developed by pharmaceutical firms Eisai, Biogen and BioArctic. Donanemab, marketed as Lormalzi in Singapore and Kisunla in other countries, is developed by Eli Lilly. Top stories Swipe. Select. Stay informed. Singapore Sewage shaft failure linked to sinkhole; PUB calling safety time-out on similar works islandwide Singapore Tanjong Katong Road sinkhole did not happen overnight: Experts Singapore Workers used nylon rope to rescue driver of car that fell into Tanjong Katong Road sinkhole Asia Singapore-only car washes will get business licences revoked, says Johor govt World Food airdropped into Gaza as Israel opens aid routes Sport Arsenal beat Newcastle in five-goal thriller to bring Singapore Festival of Football to a close Singapore Benchmark barrier: Six of her homeschooled kids had to retake the PSLE Asia S'porean trainee doctor in Melbourne arrested for allegedly filming colleagues in toilets since 2021 Both are intravenous injections – lecanemab is administered every two weeks over about 1½ years, and donanemab is administered every four weeks over the same period. How effective are they? During clinical trials, both drugs demonstrated the ability to slow Alzheimer's disease. Findings from the clinical trial of lecanemab, published in the New England Journal of Medicine, showed that it slowed decline for people with early Alzheimer's disease by about 27 per cent to 37 per cent. Meanwhile, results from donanemab's Phase 3 clinical trial, published in the Journal of the American Medical Association, showed that the drug slowed cognitive decline by about 20 per cent to 29 per cent. Eisai medical director Amitabh Dash said lecanemab differs from existing drugs, which treat symptoms and manage memory or behavioural issues only temporarily. 'It works by clearing these protofibrils and amyloid plaques, which are believed to contribute to the progression of the disease,' said Dr Dash. Protofibrils refer to protein aggregrates such as beta-amyloids. Lecanemab was approved by the US Food and Drug Administration (FDA) in 2023, and by the Medicines and Healthcare products Regulatory Agency in Britain in 2024. Donanemab received FDA approval in 2024, and was also approved in Britain that year. In Singapore, the Health Sciences Authority (HSA) confirmed that the two drugs had been approved for use earlier in 2025. 'They are prescription-only medicines, and the treatment should be initiated by a physician experienced in the diagnosis and treatment of Alzheimer's disease,' HSA told The Straits Times. What are the side effects? For both drugs, the common side effects include infusion-related reactions such as fever, body aches and joint pains. However, the drugs have also been known to cause amyloid-related imaging abnormalities, known as Aria, a condition that can cause brain swelling or bleeding. In many cases, the condition is asymptomatic. But in more severe cases, it can cause seizures, or even death in rare instances. 'MRI monitoring is recommended during treatment to manage this risk safely,' said Dr Dash, referring to magnetic resonance imaging. What has been the response in Singapore to the drugs? Doctors in Singapore who have prescribed lecanemab described their experience as largely positive. Dr Lee Kim En, a neurologist at Mount Elizabeth Hospital, prescribed the drug to 27 patients, who had symptoms such as memory loss affecting their daily lives and difficulty in performing familiar tasks, including handling personal and financial matters. Most patients had shown a favourable response to the treatment, with a slowing in disease progression and preservation of cognition. 'Only one patient experienced mild confusion, disorientation for several hours after his first treatment,' Dr Lee added. He described lecanemab as a 'breakthrough treatment' for patients in the early stages of Alzheimer's disease. 'Without intervention, the time course of deterioration may take four to eight years, requiring full-time care and assistance for all aspects of daily living,' he said. Associate Professor Adeline Ng, a senior consultant at the National Neuroscience Institute's neurology department, had prescribed lecanemab to two women below the age of 65 who were diagnosed with mild Alzheimer's and had gradual mild cognitive decline. While on treatment, they were able to be more engaged with their families and maintain their ability to look after their daily needs, Prof Ng said, noting that neither had side effects. She intends to continue prescribing lecanemab, describing the treatment as 'the start of an era of new drug treatments' that could potentially modify the disease course for patients. Prof Ng stressed that such drugs are effective only in the early stages of Alzheimer's and are not a cure. Rather, they delay progression to the next stage of the disease by about six to eight months. 'The drug is also not suitable for some patients, such as those who have had previous strokes or who take certain blood thinning medication, due to the increased risk of bleeding in the brain,' she added. What are the costs? One factor that could stand in the way of wider acceptance of these drugs is their costliness. In the United States, lecanemab treatment is priced at US$26,500 (S$33,900) per year, while donanemab costs about US$32,000 annually. Britain's National Institute for Health and Care Excellence has declined to recommend both drugs for routine use under the publicly funded National Health Service, due to the high costs of purchasing and administering the drugs, and a lack of evidence on their long-term effects. In Singapore, the prices of the two drugs are not publicly available. However, the Ministry of Health said it is evaluating the clinical efficacy and cost-effectiveness of the two drugs to decide whether to subsidise them in the future. Dr Dash said such drugs represent a paradigm shift in the approach to Alzheimer's, noting that early diagnosis and treatment will become increasingly important due to the ageing populations in Singapore and across the region. 'The availability of Leqembi may drive healthcare systems to adopt biomarker-based diagnosis, improve infrastructure for safe infusion and monitoring, and offer patients more hope for slowing disease progression rather than only managing symptoms,' he said. Simply Science is a series that looks at the science behind everyday questions.
